Seungyeon Han, Equity Research Analyst at NH Investment and Securities, shared a post on LinkedIn:
“Here’s my belated upload of the 2025 ASCO review report, ‘Pivot to Asia.’
I hope you find it useful for understanding recent global oncology R and D trends, and I’d be glad to hear any of your thoughts or perspectives.
From May 30 – June 3, we attended the American Society of Clinical Oncology (ASCO) —the most influential oncology conference worldwide, where late-stage clinical data are presented and often shape real-world medical practice among oncologists.
In this report, we classify global oncology R and D directions into two major trends and analyze their latest clinical data and big-pharma development strategies:
Trend 1: ADC and PD-(L)1 × VEGF combinations
ADCs remained the highlight of the conference, with two Phase III readouts(ENHERTU (fam-trastuzumab deruxtecan-nxki) HCP TRODELVY (sacituzumab govitecan-hziy) HCP) in first-line treatment settings leading to upward revisions of overall industry sales forecasts.
For bispecific antibody immuno-oncology agents(Summit Therapeutics, Inc.), we take a wait-and-see stance ahead of additional data—HARMONi-6 and BNT-327 (TNBC)—expected later this year. Immune-cytokine combinations (e.g., IL-2) also deserve attention.
Trend 2: RPT, TPD, and AI-driven diagnostics
While these modalities still need time to reach the global mainstream, their developmental trajectories are becoming clearer. We see potential in RPT-IO combinations, advances in DAC technologies for TPD, and progress in AI-based biomarker and companion-diagnostic platforms.”
More posts featuring ASCO on OncoDaily.